Efficacy of Obinutuzumab

In chronic lymphocytic leukemia (CLL), obinutuzumab delayed disease progression in previously untreated patients who had other diseases and were therefore ineligible for fludarabine-based treatments. In a major study involving 781 patients, those who received otuzumab and chlorambucil lived longer without worsening of their disease than those who received chlorambucil alone. Likewise, patients who received otuzumab and chlorambucil survived longer without worsening of their disease than those who received rituximab and chlorambucil.

In follicular lymphoma (FL), otuzumab showed benefit in a major study involving 1,202 patients with previously untreated FL. During an average follow-up period of approximately three years, 17% of patients treated with otuzumab died or had their disease worsened. Otuzumab was also investigated in a study involving 321 FL patients who had failed or discontinued treatment with rituximab. Patients who receivedoctuzumab plus bendamustine lived longer without worsening of their disease than those who received bendamustine alone.

The original drug of Otuzumab has been launched in China and has entered the scope of medical insurance, but it is only reimbursed for patients who meet the indications. Specifications The price of 1000mg (40ml)*1 bottle may be around 9,000 yuan, which is a strictly controlled drug. The price of the Turkish version of Otuzumab Specifications1000mg/40ml per box listed overseas may be around RMB 10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold domestically and abroad are basically the same. There is currently no generic version of Otuzumab produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.